Finally An Attractive Entry Point Into Novo Nordisk
Novo Nordisk's shares plummeted due to disappointing trial results for CagriSema, with patients achieving only 22.7% weight ...
Why Eli Lilly, Novo Nordisk, and Viking Therapeutics Stocks All Dropped on Tuesday
Turning to 2025 guidance, Lilly noted that new medicines and new uses of existing medicines, expansion of production, and ...
Columbus joins national fight accusing drug manufacturers of inflating insulin prices
According to the American Diabetes Association, approximately 8.4 million people in the United States need insulin to survive ...
Novo Nordisk: From Peak Performance To Needing A Booster Shot
I'm cautious about Novo Nordisk's short-term prospects due to the recent selloff, but see long-term potential with high ...
Better Buy: Novo Nordisk vs. AstraZeneca
Novo Nordisk's prospects look attractive despite a recent clinical setback. AstraZeneca would be performing well if not for ...
Novo Nordisk's valuation now more attractive: Bernstein
Investing.com -- Bernstein analysts highlighted a more attractive valuation for Novo Nordisk (NYSE: NVO) following recent ...
FierceBiotech1h
Boehringer’s phase 3 schizophrenia program misses primary goal
Boehringer Ingelheim’s investigational schizophrenia candidate has failed to improve cognitive impairment or functioning in a ...
Novo Nordisk: Excellent Opportunity To Buy The Dip
Novo Nordisk's financial strength is evident through its 74% historical average ROIC and 85% gross margin. See why I rate NVO ...